E Fund Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

E Fund Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-10,177	Closed	-$41.6K	–	372
2024 Q2	$41.6K	Sell	10,177 -3,906	-28%	-$43.6K	﹤0.01%	318
2024 Q1	$222K	Sell	14,083 -5,257	-27%	-$72.3K	0.01%	326
2023 Q4	$293K	Buy	19,340 +9,033	+88%	+$132K	0.02%	232
2023 Q3	$207K	Sell	10,307 -3,185	-24%	-$80.8K	0.02%	254
2023 Q2	$381K	Buy	13,492 +1,671	+14%	+$40.1K	0.03%	181
2023 Q1	$203K	Sell	11,821 -195	-2%	-$3.95K	0.01%	298
2022 Q4	$242K	Sell	12,016 -612	-5%	-$13.2K	0.02%	267
2022 Q3	$274K	Sell	12,628 -1,728	-12%	-$47.3K	0.03%	247
2022 Q2	$403K	Buy	14,356 +8,277	+136%	+$219K	0.04%	188
2022 Q1	$280K	Buy	+6,079	New	+$328K	0.01%	224

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

E Fund Management's ZNTL Position: Q3 2024 in Review

E Fund Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 10,177 shares — an estimated $41.6K sold.

E Fund Management first reported a position in ZNTL in Q1 2022 and held it in 10 quarters. The position peaked at $403K in Q2 2022. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

E Fund Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
E Fund Management sold 10,177 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $41.6K.
E Fund Management first reported a position in Zentalis Pharmaceuticals in Q1 2022 and held it in 10 quarters.
E Fund Management's Zentalis Pharmaceuticals position peaked at $403K in Q2 2022.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on E Fund Management's 13F filing for Q3 2024, filed 13 Nov 2024.